Navigation Links
Are angiotensins involved in the hemodynamic changes of cirrhosis patients?
Date:6/11/2009

Liver cirrhosis has been recently studied in the light of the new view of the renin angiotensin system (RAS). While the angiotensin converting enzyme (ACE)-Ang 2-AT1 receptor arm contributes to liver tissue injury and fibrosis and the maintenance of basal vascular tonus in non-compensated cirrhosis, the activation of the ACE2-Ang-(1-7)-Mas receptor arm exerts anti-fibrotic actions and probably has also a role in arterial vasodilation in liver cirrhosis. In a previous study published last year in WJG by the same research group, it was shown that chronic treatment with propranolol in cirrhotic patients was characterized by marked changes in the precursors of the RAS cascade (renin and Ang 1 with repercussions on the 2 main RAS components, Ang 2 and Ang-(1-7), in the splanchnic and peripheral circulation. Therefore, the circulating profile of RAS components at different stages of liver cirrhosis and their role in hemodynamic changes of cirrhosis remained unclear.

A research article to be published in May 28, 2009 in the World Journal of Gastroenterology addressed this issue. The research team led by Prof. Santos from the Federal University of Minas Gerais measured the circulating levels of angiotensins in patients at different stages of liver cirrhosis by radioimmunoassay, and further evaluated the influence of RAS components on hemodynamic changes during liver transplantation.

The study showed that the progression of liver dysfunction is characterized by marked changes in circulating Ang-(1-7) and Ang 2 levels. In the initial stages, there were a predominance of Ang-(1-7) rather than Ang 2. On the other hand, advanced stages of cirrhosis showed an activation of the peripheral and splanchnic RAS, and a deviation toward the formation of Ang-(1-7) in the splanchnic circulation. Furthermore, there was a positive correlation between the Ang-(1-7)/Ang 2 ratio and cardiac output and a negative correlation between this ratio and systemic vascular resistance, indicating that the final functional effects of the RAS may reflect a balance between these 2 opposing peptides.

The relationship between Ang-(1-7) and Ang 2 may play a role in hemodynamic changes of human cirrhosis. The peptide Ang-(1-7) probably predominates in the peripheral circulation in the initial stages of human cirrhosis and in the splanchnic circulation in the advanced stages, both contributing to a reduction in vascular resistance and consequently to hyperdynamic circulation. In the peripheral circulation of patients with advanced cirrhosis, when compared to the splanchnic circulation, Ang 2 probably leads to extra-splanchnic vasoconstriction. Although further studies with a larger number of patients should address the precise role of RAS in human cirrhosis, this research opens the possibility that future therapies interfering with the RAS in both the systemic and splanchnic circulation should lead to more success in the management of the hemodynamic changes in human cirrhosis.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Protein Involved in Addiction Changes Brain Circuitry
2. NPs-NPR-B/pGC-cGMP signal pathway is involved in diabetic gastroparesis
3. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
4. AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care
5. Video: AHRQ And Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care
6. Metro Parents Second Annual Living With Autism Workshop Features Local Experts Who Are Intimately Involved in Improving the Lives of These Special Children
7. Americas Watchdog Calls On President Obama To Get Involved With The Toxic Chinese Drywall Disaster--Now
8. Emmi + KidsHealth = Prescription for Informed and Involved Patients
9. Study finds most adolescents sent to group homes still involved with drugs/crime seven years later
10. Progress Reported Against Gene Involved in Hepatitis C
11. U-M Researchers ID Gene Involved in Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: